AIM VACCINE (06660): Fully integrating the DeepSeek large model to achieve the strategic upgrade of "AI + smart vaccine enterprise".

AIM VACCINE (06660) announced that as a leading vaccine company in China, the group actively responds to the national "AI+" industry development strategy, and has fully deployed the DeepSeek large model to promote the application of the R1 version across all business scenarios in the group, achieving the goals of reducing costs, improving quality, and increasing efficiency throughout the vaccine lifecycle. In order to build an intelligent vaccine research and development system, the group will use the DeepSeek large model to obtain higher quality candidate vaccines through processes such as discovery, design, and manufacturing. By integrating data from various biological information databases, and utilizing a combination of pre-trained protein language models and graph neural network architectures, the group aims to achieve intelligent antigen target selection and dynamic analysis of conservative regions. Additionally, by accessing real-time mutation monitoring data streams, the group aims to predict the future direction of pathogen mutations using long short-term memory networks, dynamically analyze conservative regions, and predict broad-spectrum antigenic epitopes. The group will also utilize DeepSeek in combination with generative models and deep learning technologies to optimize mRNA vaccine sequence design and stability. By predicting mRNA secondary structures and intelligently designing efficient component combinations based on the genetic expression codon preferences of host cells, the stability and translation efficiency of mRNA can be improved to generate the optimal sequence. Furthermore, the group is exploring the use of the DeepSeek AI framework to optimize process parameters in order to increase antigen production yields and quality. In terms of clinical operations, the group has fully deployed the DeepSeek R1 version to interface with clinical trial management systems, EDC (electronic data capture systems), central randomization systems, drug surveillance systems, and laboratory management systems. This integration drives the intelligent implementation of the entire clinical trial process from data collection and analysis to decision-making, shortening the clinical trial cycle and enhancing data accuracy and compliance. This enables researchers to focus more on advancing clinical projects, quality evaluation, ethical judgments, and patient care in core areas, providing technical support for rapid vaccine market approval. While reducing costs, this significantly improves the efficiency and quality of clinical research. In terms of production and quality management, the group has fully deployed the DeepSeek R1 version to interface with MES systems, LIMS systems, and SCADA systems. This allows for deep learning of production, inspection data, and real-time monitoring data, the construction of production and quality inspection management prediction models, optimization of production processes, improved production efficiency, shortened production cycles, and reduced energy consumption. By utilizing AI to analyze production and inspection-related quality data, potential risks can be identified, preventive quality control can be implemented, ensuring high standards of compliance for each batch of vaccines, further enhancing the stability, reliability, and consistency of vaccine quality. In terms of marketing management, the group has fully deployed the DeepSeek R1 version to interface with CRM systems for comprehensive integration. This enhances data analysis efficiency and value extraction, providing data and decision support for company management and strategic development. Based on historical sales data and market demand changes, AI models are used to flexibly analyze market data and make precise forecasts. Additionally, in company management, talent training, financial management, and other areas, the DeepSeek R1 version is fully integrated to build an enterprise knowledge base and further enhance the company's management level. By fully integrating the DeepSeek large model, the group will deeply penetrate AI technology across the entire industry chain of research and development, production, sales, and management, providing cutting-edge solutions for global immunization and disease control.